Akademik Veri Yönetim Sistemi
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.18, sa.5, ss.444-448, 1995 (SCI-Expanded)
This article presents a young patient affected with non-Hodgkin lymphoma who developed acute myocardial infarction 7 days after treatment with epirubicin (90 mg/m(2), day 1), cyclophosphamide (600 mg/m(2), day 1), vincristine (2 mg, day 1), prednisolone (100 mg, days 1-5), and ondansetron (3 X 4 mg/day, days 1-2). Six months after the myocardial infarction the patient had no further cardiac complications after treatment with the cyclophosphamide, vincristine, and ondansetron chemotherapy regimen. Epirubicin was considered to play an important role in the production of infarction, and the probable mechanisms of epirubicin-induced myocardial infarction are discussed.